DOCSLIB.ORG

Discontinuation of Urate-Lowering Drugs: a Systematic Review Protocol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Discontinuation of Urate-Lowering Drugs: a Systematic Review Protocol Discontinuation of urate-lowering drugs: a systematic review protocol Virginie Beslon, Perrine Moreau, Annabel Maruani, Hubert Maisonneuve, Bruno Giraudeau, Jean-Pascal Fournier ADMINISTRATIVE INFORMATION Registration PROSPERO registration number: Review team Virginie Beslon, Département de médecine générale, Université de Nantes, France ; [email protected] Perrine Moreau, Département de médecine générale, Université de Nantes, France ; [email protected] Annabel Maruani, Services de dermatologie, CHRU de Tours, Université François Rabelais, Tours, France ; [email protected] Hubert Maisonneuve, Unité des Internistes Généralistes et Pédiatres, Faculté de Médecine, Université de Genève, Suisse ; [email protected] Bruno Giraudeau, INSERM CIC 1415, CHRU de Tours, Université François-Rabelais, Tours, France ; [email protected] Jean-Pascal Fournier, Département de médecine générale, EA 4275-SPHERE, Université de Nantes, France ; [email protected] Contact details Jean-Pascal Fournier (guarantor) Département de médecine générale, Université de Nantes EA 4275-SPHERE, Biostatistique, Recherche Clinique et Mesures Subjectives en Santé, Université de Nantes 1 rue, Gaston Veil, 44000, Nantes, France [email protected] Contributions 1. Draft the protocol: VB, PM, AM, HM, BG, JPF 2. Study selection: VB, PM, JPF 3. Extract data from studies: VB, PM, JPF 4. Carry out the analysis: VB, PM, JPF 5. Interpret the analysis: VB, PM, AM, HM, BG, JPF 6. Draft the final review: VB, PM, JPF 7. Critical revision of the review for important intellectual content: VB, PM, AM, HM, BG, JPF Anticipated or actual start date December 30, 2015 Anticipated completion date October 30, 2016 Dissemination plans This paper will be submitted to a leading journal in this field. We can also use this paper for oral or poster presentation in any leading conference at national or international level. Funding sources/sponsors None Conflicts of interest The authors have no conflict of interest to report. INTRODUCTION Rationale Gout is an urate crystal deposition disease and the most common rheumatic disease in adults (0.9% of adults in France and 3.9 % in the US) (1,2). In the last decade the prevalence of gout has raised worldwide, related with the increase in age of population, obesity, and alcohol consumption (3). Urate-lowering therapy is recommended in case of symptomatic hyperuricemia (acute gouty arthritis, tophi, urate nephropathy, and uric acid nephrolithiasis) and can be used prophylactically to prevent chemotherapy-induced hyperuricemia. Allopurinol is the most commonly used urate- lowering drug, and acts through inhibition of xanthine oxidase. Other urate-lowering drugs include febuxostat, probenecid, sulfinpyrazone, benzbromarone. These drugs aim at reducing acid uric level below 360 mmol/L (6.0 mg/ddL) (4). Urate-lowering drugs are also widely used off-label for treating asymptomatic hyperuricemia (50% to 56.8% of patients with allopurinol in France) (5–7). According to experts, urate-lowering drugs should be used in the long-term, and even indefinitely. However, compliance to urate-lowering drugs is poor in practice (8,9). High spontaneous withdrawal rates motivate the global assessment of the effects of discontinuing these drugs. Objectives The overall purpose of this systematic review is to evaluate the recurrence of gouty arthritis, tophi, urate nephropathy, or uric acid nephrolithiasis after discontinuation of urate-lowering drug, and time to clinical effects. Secondary aims include the assessment of adverse events and urate-lowering drugs reintroduction rates. METHODS Eligibility criteria We will include all types of studies [all randomized control trials (RCTs), clinical control trials (CCTs) and observational studies (case control, longitudinal study)], investigating the effect of discontinuation of urate-lowering drugs in adults (18 years of age and over). We will include studies assessing discontinuation of any urate-lowering drug: xanthine oxidase inhibitor drug (allopurinol, febuxostat) or conventional uricosuric drug (probenecid, sulfinpyrazone, benzbromarone). Studies assessing switches between urate-lowering drugs will not be included. Studies assessing short-term effects (less than 3 months) of urate-lowering drugs will not be included. Studies will be included regardless of the urate-lowering drug indication (acute gouty arthritis, tophi, urate nephropathy, uric acid nephrolithiasis, prophylaxis of chemotherapy-induced hyperuricemia, asymptomatic hyperuricemia, other). If the same participants are assessed in different time points or in multiple studies, we will extract and analyze all the data of different follow-up periods, and choose those with the longest follow-up for analysis. The search will be limited by language (English, French, and Spanish), and only studies including human subjects will be included. Information sources We will search the following databases from inception to current date: The Cochrane Central Register of Controlled Trials (CENTRAL), via the Cochrane Library, Wiley InterScience (www.thecochranelibrary.com), MEDLINE, EMBASE, Science Citation Index (web of science), and ClinicalTrials.gov (www.ClinicalTrials.gov). We will also perform hand search articles from reference lists of articles. We will also perform manual hand search through conference abstracts of the American College of Rheumatology/The Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meetings (2006-2015) and European League Against Rheumatism (EULAR) Annual Congresses (2002-2015). Search strategy The following search strategy for MEDLINE has been developed in collaboration with a librarian: Allopurinol [All Fields] OR febuxostat [All Fields] OR probenecid [All Fields] OR benzbromarone [All Fields] OR urate lowering [All Fields] OR xanthine oxidase inhibitor [All Fields] OR antihyperuricemic [All Fields] OR anti-hyperuricemic [All Fields] OR gout suppressants [All Fields] AND stop* OR withdr* [All Fields] OR cess* [All Fields] OR ceas* [All Fields] OR discontinu*[All Fields] OR withhold* [All Fields] OR step-down [All Fields] OR deprescri* [All Fields] OR taper* [All Fields] OR halt* [All Fields] OR drop-out [All Fields] [All Fields] NOT (animals [Mesh] NOT humans [Mesh]) Subsequent search strategies will be derived from the MEDLINE strategy and adapted for each database. Study records - Data management and selection process Three reviewers [VB, PM and JPF] will independently screen the titles and abstracts for inclusion of all the potential studies using Abstarckr. Any discrepancies will be discussed and resolved by consensus. Full copies of all studies deemed potentially relevant will be obtained and the same three reviewers [VB, PM and JPF] will independently assess these for inclusion; any disagreements will be resolved by consensus. We will identify and exclude duplicates and collate multiple reports of the same study so that each study, rather than each report, is the unit of interest in the review. We will record the selection process in sufficient detail to complete a PRISMA flow diagram. - Data collection process Two review authors (VB and PM) will extract data independently; discrepancies will be identified and resolved by consulting the third author (JPF). A standardized, pre-piloted form will be used to extract data from the included studies, for assessment of study quality and evidence synthesis. Data items Extracted information will include: 1. Methods: study design, total duration of study, number of study centers and location, study setting, follow-up duration after ULT discontinuation, and date of study. 2. Participants: N, mean age, age range, sex, disease duration, severity of condition, diagnostic criteria, duration of urate-lowering drug treatment before discontinuation; inclusion criteria, and exclusion criteria. 3. Interventions: type of discontinuation (abrupt, titration), comparison (if applicable), concomitant medications, excluded medications. 4. Outcomes: recurrence of gouty arthritis, tophi, urate nephropathy, or uric acid nephrolithiasis adverse events, urate-lowering drugs reintroduction, serum urate level, time of measurement. 5. Notes: funding for trial, and notable declarations of interest of trial authors. Risk of bias in individual studies Two review authors (VB and PM) will independently assess risk of bias for each study. We will resolve any disagreements by discussion or by involving another author (JPF). We will use the Cochrane Collaboration’s tool for assessing risk of bias in randomized trials for the RCT and the ACROBAT-NSRI tool for the non-randomized studies. In case of non-comparative studies, the first 8 items of the MINORS checklist will be used to assess the quality of included studies. Data synthesis After extracting data from each study, we will insert the obtained data into structured tables. We will provide a narrative synthesis of the findings from the included studies, structured around the type of intervention, population characteristics, and type of outcomes. We anticipate that there will be limited scope for meta-analysis because of the range of different outcomes measured across the small number of existing studies. Additional analyses We plan to carry out the following subgroup analyses if available data is sufficient: 1. Age group 2. Indication of urate-lowering drug 3. Duration of urate-lowering treatment at baseline 4. Type of urate-lowering drug 5. Dose of urate-lowering drug Meta-biases
Load more

Recommended publications
  • Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia DINESH KHANNA,1 JOHN D
    Arthritis Care & Research Vol. 64, No. 10, October 2012, pp 1431–1446 DOI 10.1002/acr.21772 © 2012, American College of Rheumatology SPECIAL ARTICLE 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia DINESH KHANNA,1 JOHN D. FITZGERALD,2 PUJA P. KHANNA,1 SANGMEE BAE,2 MANJIT K. SINGH,3 TUHINA NEOGI,4 MICHAEL H. PILLINGER,5 JOAN MERILL,6 SUSAN LEE,7 SHRADDHA PRAKASH,2 MARIAN KALDAS,2 MANEESH GOGIA,2 FERNANDO PEREZ-RUIZ,8 WILL TAYLOR,9 FRE´ DE´ RIC LIOTE´ ,10 HYON CHOI,4 JASVINDER A. SINGH,11 NICOLA DALBETH,12 SANFORD KAPLAN,13 VANDANA NIYYAR,14 DANIELLE JONES,14 STEVEN A. YAROWS,15 BLAKE ROESSLER,1 GAIL KERR,16 CHARLES KING,17 GERALD LEVY,18 DANIEL E. FURST,2 N. LAWRENCE EDWARDS,19 BRIAN MANDELL,20 H. RALPH SCHUMACHER,21 MARK ROBBINS,22 2 7 NEIL WENGER, AND ROBERT TERKELTAUB Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determi- nation regarding their application to be made by the physician in light of each patient’s individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed or endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice.
    [Show full text]
  • Colchicine and Probenecid | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Colchicine and Probenecid This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. What is this drug used for? It is used to prevent gouty arthritis. What do I need to tell my doctor BEFORE I take this drug? For all patients taking this drug: If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have any of these health problems: Blood problems or kidney stones. If you have any of these health problems: Kidney disease or liver disease. If you are pregnant or may be pregnant. Do not take this drug if you are pregnant. If you are taking a salicylate drug like aspirin. If you have liver or kidney problems and you take certain other drugs. Very bad and sometimes deadly side effects have happened in these people. There are many drugs that can do this. Ask your doctor or pharmacist if you are not sure. Children: If the patient is a child younger than 2 years of age. Do not give this drug to a child younger than 2 years of age. Colchicine and Probenecid 1/6 This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems.
    [Show full text]
  • Gout Management in Swiss Primary Care – a Retrospective Observational Study
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2020 Gout management in Swiss primary care - a retrospective observational study Meier, Rahel ; di Gangi, Stefania ; Valeri, Fabio ; Rosemann, Thomas ; Zechmann, Stefan Abstract: BACKGROUND Gout is the most common form of inflammatory arthritis worldwide and its prevalence is rising. In Switzerland, there are no data available on the characteristics and treat- ment of gout patients. In this study, we aimed to describe numbers of patients affected by gout and hyperuricaemia and unveil approaches Swiss primary care physicians (PCPs) use for the management. METHODS This was a retrospective observational study using electronic medical routine nbsp;data pro- vided from 242 Swiss PCPs. Included were all their patients receiving urate-lowering therapy (ULT), with a diagnostic code for gout or who had a serum uric acid (SUA) measurement. According to their disease status, patients were classified into four subgroups (normal urate, hyperuricaemia, untreated gout, treated gout). For treatment analysis, patients with SUA measurements before and after ULT initiation were in- cluded. Comorbidities and risk factors for secondary causes relevant in the context of gout were collected. Outcomes were prevalence of gout and hyperuricaemia, characteristics of patients according to subgroup, number of SUA measurements, levels of SUA and patients who reached the treatment goal of a SUA level lt;360 micro;mol/l. RESULTS We assessed 15,808 patients and classified them into the subgroups. This yielded a prevalence of 1.0% for gout and 1.2% for hyperuricaemia. 2642 patients were diagnosed with gout of whom 2420 (91.6%) received a ULT.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Antihyperuricemics Review 10/25/2010
    Antihyperuricemics Review 10/25/2010 Copyright © 2009 – 2010 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 10101 Alliance Rd, Ste 201 Cincinnati, Ohio 45242 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. Antihyperuricemics Review FDA-Approved Indications1,2 Drug Manufacturer Indication(s) allopurinol generic - Management of patients with signs and symptoms (Zyloprim® )3 of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).
    [Show full text]
  • Febuxostat: a Safe and Effective Therapy for Hyperuricemia and Gout
    DRUG EVALUATION Febuxostat: a safe and effective therapy for hyperuricemia and gout Natasha Jordan† & Febuxostat is a novel, nonpurine, selective xanthine oxidase inhibitor and is a potential Geraldine M McCarthy alternative to allopurinol for patients with hyperuricemia and gout. Unlike allopurinol, which †Author for correspondence undergoes renal elimination, febuxostat is metabolized via hepatic conjugation and Mater Misericordiae oxidation. Phase III studies have shown that febuxostat, at a once-daily dose of 80, 120 or University Hospital, Eccles St. Dublin 7, Ireland 240 mg (safety dose), is more effective than allopurinol (300 mg) in reducing and Tel.: + 35 316 405 514; maintaining serum urate concentrations lower than 6 mg/dl. Reductions in gout flares and [email protected] tophus areas with febuxostat treatment are similar to those occurring with allopurinol therapy. Patients with moderate renal impairment can achieve significant serum urate reductions, without dose adjustments. Therefore, febuxostat represents a viable treatment choice, with documented efficacy and safety in hyperuricemia and gout. Gout is a disease in which tissue deposition of agents) or by decreasing urate synthesis (xan- monosodium urate crystals occurs as a result of thine oxidase inhibitors). These therapeutic hyperuricemia, defined as a serum urate concen- options are not without their limitations. tration that exceeds the limit of solubility (∼6.8 mg/dl [400 µmol/l]). Clinical manifesta- Market overview tions include recurrent attacks of acute inflam- Allopurinol is a competitive inhibitor of xanthine matory arthritis, accumulation of urate crystals oxidase, preventing the oxidation of xanthine to in the form of tophaceous deposits and nephro- uric acid. Allopurinol and its active metabolite, pathy.
    [Show full text]
  • Vinblastine and Sulfinpyrazone Export by the Multidrug Resistance Protein MRP2 Is Associated with Glutathione Export
    British Journal of Cancer (2000) 83(3), 375–383 © 2000 Cancer Research Campaign doi: 10.1054/ bjoc.2000.1262, available online at http://www.idealibrary.com on Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export R Evers1,4, M de Haas1, R Sparidans2, J Beijnen2, PR Wielinga3, J Lankelma3 and P Borst1 1Division of Molecular Biology and Center of Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Pharmacy, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands; 3Academic Hospital Vrije Universiteit, Department of Medical Oncology, Room BR232, PO Box 7057, 1007 MB Amsterdam, The Netherlands; 4Present address Georg-Speyer-Haus, Paul Ehrlich straße 42–44, 60596 Frankfurt am, Germany Summary The multidrug resistance proteins MRP1 and MRP2 are members of the same subfamily of ATP-binding cassette transporters. Besides organic molecules conjugated to negatively charged ligands, these proteins also transport cytotoxic drugs for which no negatively charged conjugates are known to exist. In polarized MDCKII cells, MRP1 routes to the lateral plasma membrane, and MRP2 to the apical plasma membrane. In these cells MRP1 transports daunorubicin, and MRP2 vinblastine; both transporters export reduced glutathione (GSH) into the medium. We demonstrate that glutathione transport in MDCKII-MRP1 cells is inhibited by the inhibitors of organic anion transporters sulfinpyrazone, indomethacin, probenecid and benzbromarone. In MDCKII-MRP2 cells, GSH export is stimulated by low concentrations of sulfinpyrazone or indomethacin, whereas export is inhibited down to control levels at high concentrations. We find that unmodified sulfinpyrazone is a substrate for MRP2, also at concentrations where GSH export is inhibited.
    [Show full text]
  • Highly Eribulin-Resistant KBV20C Oral Cancer Cells Can Be Sensitized By
    ANTICANCER RESEARCH 37 : 4139-4146 (2017) doi:10.21873/anticanres.11801 Highly Eribulin-resistant KBV20C Oral Cancer Cells Can Be Sensitized by Co-treatment with the Third-generation P-Glycoprotein Inhibitor, Elacridar, at a Low Dose YUJIN PARK*, JI-YEON SON*, BYUNG-MU LEE, HYUNG SIK KIM and SUNGPIL YOON School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea Abstract. Background/Aim: Eribulin mesylate, also called resistant cancer cells can be sensitized with cyclosporine A Halaven ® (HAL), was recently developed as a microtubule- or elacridar, specific P-gp inhibitors that exert their effects targeting drug and is used in the clinic for resistant or at a low dose. These findings provide important information metastatic cancer. Previously, we showed that P-glycoprotein regarding the sensitization of highly HAL-resistant cells with (P-gp)-overexpressing KBV20C oral cancer cells are highly selective P-gp inhibitors and indicate that elacridar may be resistant to HAL compared to sensitive KB cells. This used to treat such highly HAL-resistant cancer cells. qualitative study was designed to identify specific P-gp inhibitors that increase the sensitivity of highly resistant Anti-mitotic drugs, which target different binding sites on cancer cells to HAL. Materials and Methods: In order to tubulin, are widely used for treating different types of cancer identify functional P-gp inhibitors, HAL-treated KBV20C (1, 2). These compounds inhibit mitosis by targeting cells were co-treated with P-gp inhibitors, verapamil, microtubules and preventing their polymerization or elacridar, cyclosporine A, mitotane, piperine, fumagillin, depolymerization (3, 4). Eribulin, also called Halaven ® curcumin, indomethacin, probenecid, sulindac, tesmilifene, (HAL), was recently developed and used in the clinic to treat and C-4.
    [Show full text]
  • 2020 American College of Rheumatology Guideline for the Management of Gout
    Arthritis Care & Research Vol. 0, No. 0, June 2020, pp 1–17 DOI 10.1002/acr.24180 © 2020, American College of Rheumatology ACR GUIDELINE FOR MANAGEMENT OF GOUT 2020 American College of Rheumatology Guideline for the Management of Gout John D. FitzGerald,1 Nicola Dalbeth,2 Ted Mikuls,3 Romina Brignardello-Petersen,4 Gordon Guyatt,4 Aryeh M. Abeles,5 Allan C. Gelber,6 Leslie R. Harrold,7 Dinesh Khanna,8 Charles King,9 Gerald Levy,10 Caryn Libbey,11 David Mount,12 Michael H. Pillinger,5 Ann Rosenthal,13 Jasvinder A. Singh,14 James Edward Sims,15 Benjamin J. Smith,16 Neil S. Wenger,17 Sangmee Sharon Bae,17 Abhijeet Danve,18 Puja P. Khanna,19 Seoyoung C. Kim,20 Aleksander Lenert,21 Samuel Poon,22 Anila Qasim,4 Shiv T. Sehra,23 Tarun Sudhir Kumar Sharma,24 Michael Toprover,5 Marat Turgunbaev,25 Linan Zeng,4 Mary Ann Zhang,20 Amy S. Turner,25 and Tuhina Neogi11 Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to the recommendations within this guideline to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient’s individual circumstances. Guidelines and recommen- dations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed and endorsed by the ACR are subject to periodic revision as warranted by the evolution of med- ical knowledge, technology, and practice.
    [Show full text]
  • 204820Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204820Orig1s000 SUMMARY REVIEW SUMMARY REVIEW OF REGULATORY ACTION Date: September 26, 2014 From: Badrul A. Chowdhury, MD, PhD Director, Division of Pulmonary, Allergy, and Rheumatology Products, CDER, FDA Subject: Division Director Summary Review NDA Number: 204820 Applicant Name: Hikma Pharmaceuticals, West-Ward Pharmaceuticals (US Agent) Date of Submission: March 28, 2014 (original NDA was submitted on October 5, 2012) PDUFA Goal Date: September 28, 2014 (PDUFA due date for the original NDA was August 5, 2013) Proprietary Name: Mitigare Established Name: Colchicine Dosage form: Capsules Strength: 0.6 mg in each capsule Proposed Indications: Prophylaxis of gout flares in adults and adolescents 16 years of age and older Action: Approval 1. Introduction Hikma Pharmaceuticals through their US agent West-Ward Pharmaceuticals submitted this 505 (b)(2) NDA for use of Mitigare (colchicine) capsules for prophylaxis of gout flares in adults and adolescents 16 years of age and older. The proposed dose is 0.6 mg capsule once or twice daily. The applicant relies on FDA’s finding of safety and effectiveness for the combination product Col-Probenecid (colchicine 0.5 mg and probenecid 500 mg, ANDA 84729) and published literature to support its colchicine product. In addition, the applicant conducted clinical pharmacology studies: a relative bioavailability study to support reliance on FDA’s finding of safety and effectiveness for Col-Probenecid; a food effect study; and drug-drug interaction studies to support relevant dose modification recommendations for its product when used with some other drugs. The proposed regulatory pathway and the submitted clinical pharmacology data to support this application are reasonable.
    [Show full text]
  • Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
    LEGEMIDDELSTATISTIKK 2019:2 Reseptregisteret 2014–2018 The Norwegian Prescription Database 2014–2018 Reseptregisteret 2014–2018 The Norwegian Prescription Database 2014–2018 Christian Lie Berg Kristine Olsen Solveig Sakshaug Utgitt av Folkehelseinstituttet / Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Juni 2019 Tittel/Title: Legemiddelstatistikk 2019:2 Reseptregisteret 2014–2018 / The Norwegian Prescription Database 2014–2018 Forfattere/Authors: Christian Berg, redaktør/editor Kristine Olsen Solveig Sakshaug Acknowledgement: Julie D. W. Johansen (English text) Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no / The report can be downloaded from www.fhi.no Grafisk design omslag: Fete Typer Ombrekking: Houston911 Kontaktinformasjon / Contact information: Folkehelseinstituttet / Norwegian Institute of Public Health Postboks 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN: 978-82-8406-014-9 Sitering/Citation: Berg, C (red), Reseptregisteret 2014–2018 [The Norwegian Prescription Database 2014–2018] Legemiddelstatistikk 2019:2, Oslo, Norge: Folkehelseinstituttet, 2019. Tidligere utgaver / Previous editions: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian
    [Show full text]
  • Evidence for a Postsecretory Reabsorptive Site for Uric Acid in Man
    Evidence for a Postsecretory Reabsorptive Site for Uric Acid in Man Herbert S. Diamond, James S. Paolino J Clin Invest. 1973;52(6):1491-1499. https://doi.org/10.1172/JCI107323. Research Article The effects of administration of drug combinations on uric acid excretion were studied in order to test the hypothesis that a portion of renal tubular reabsorption of uric acid occurs distal to the uric acid secretory site. Oral administration of pyrazinamide (3 g) during probenecid uricosuria (probenecid 500 mg every 6 h) decreased urate excretion from 463 μg/min following probenecid medication alone to 135 μg/min following probenecid plus pyrazinamide (P < 0.01). When a greater uricosuric effect was induced with a 2 g oral dose of probenecid, the decrement in urate excretion which followed pyrazinamide administration (3 g) was more pronounced (2,528 μg/min following probenecid alone, 574 μg/min following probenecid plus pyrazinamide). Results were similar when an 800 mg oral dose of sulfinpyrazone was given in place of probenecid (1,885 μg/min following sulfinpyrazone alone, 475 μg/min following sulfinpyrazone plus pyrazinamide). Thus, apparent urate secretion (measured as the decrease in excretion of urinary uric acid resulting from pyrazinamide administration) appeared to vary, depending upon the degree of inhibition of reabsorption produced by probenecid or sulfinpyrazone. When small doses of aspirin were administered in place of pyrazinamide to produce secretory inhibition, the results were similar. Neither probenecid nor pyrazinamide significantly altered urate excretion when administered to patients with serum salicylate levels above 14 mg/100 ml. These results are interpreted as suggesting that […] Find the latest version: https://jci.me/107323/pdf Evidence for a Postsecretory Reabsorptive Site for Uric Acid in Man HERBERT S.
    [Show full text]